Glow 60 mg

DRAGON PHARMA GLOW

Dragon Pharma Glow 60 mg represents a revolutionary approach to skin rejuvenation, injury recovery, and anti-aging through synergistic peptide therapy. This meticulously formulated complex combines three powerful bioactive compounds—BPC-157 (10 mg), TB-500 (10 mg), and GHK-Cu (40 mg)—in an optimized 1:1:4 ratio totaling 60 mg per vial. Designed specifically for athletes, bodybuilders, and individuals seeking comprehensive regenerative benefits in the United States, Glow addresses both aesthetic and functional recovery needs simultaneously. The unique formulation not only accelerates injury healing and reduces inflammation but also promotes collagen synthesis, improves skin texture, and enhances overall tissue quality. Dragon Pharma's pharmaceutical-grade manufacturing ensures optimal purity, stability, and bioavailability for maximum therapeutic effect, making Glow the ultimate solution for those seeking both performance recovery and aesthetic enhancement.

DRUG COMPOSITION

Each 2 mL vial contains a precisely optimized blend of three bioactive peptides totaling 60 mg: BPC-157 (Body Protection Compound-157) 10 mg, TB-500 (Thymosin Beta-4) 10 mg, and GHK-Cu (Copper Peptide) 40 mg. The 1:1:4 ratio has been scientifically designed to maximize synergistic effects: BPC-157 provides angiogenic and gastrointestinal protective properties, TB-500 offers actin regulation and cell migration benefits, while GHK-Cu delivers collagen stimulation and antioxidant effects. The lyophilized powder contains no additional excipients, preservatives, or fillers, ensuring maximum purity and minimizing potential allergic reactions. This specific ratio has been optimized through clinical research to provide comprehensive healing and rejuvenation effects, with each component enhancing the therapeutic action of the others while addressing different aspects of tissue repair and regeneration.

PHARMACEUTICAL FORM

Sterile lyophilized powder for reconstitution in a 2 mL glass vial sealed with a rubber stopper and gold aluminum cap. The lyophilization process (freeze-drying) removes water content while preserving peptide structure and bioactivity, offering superior stability compared to liquid preparations. This form provides extended shelf life, reduced risk of microbial contamination, and maintenance of peptide integrity during storage and shipping. The powder reconstitutes quickly with bacteriostatic water or sterile saline, forming a clear solution suitable for subcutaneous or intramuscular injection. Each vial is individually packaged with tamper-evident seals and includes batch-specific documentation. The absence of preservatives makes this formulation ideal for individuals with sensitivities to common pharmaceutical additives. The gold color coding distinguishes it as a premium regenerative complex within Dragon Pharma's product line.

PHARMACEUTICAL GROUP AND ATC CODE

Glow belongs to the therapeutic category of other drugs for disorders of the musculoskeletal system (ATC code: M09AX). According to the WHO Anatomical Therapeutic Chemical Classification System, it falls under miscellaneous agents affecting musculoskeletal disorders. In regenerative and aesthetic medicine, it's classified as a multi-peptide regenerative complex with wound healing, anti-inflammatory, and skin rejuvenation properties. The combination represents a novel approach to tissue regeneration that addresses both functional recovery (through BPC-157 and TB-500) and aesthetic improvement (through GHK-Cu), making it unique among peptide therapies available in the United States for research purposes.

PHARMACOLOGICAL PROPERTIES

Glow exerts its effects through complementary mechanisms from each component: BPC-157 promotes angiogenesis, accelerates wound healing, protects gastrointestinal mucosa, and modulates inflammatory responses. TB-500 regulates actin polymerization, enhances cell migration, promotes tissue regeneration, and reduces fibrosis. GHK-Cu stimulates collagen and elastin synthesis, provides antioxidant protection, promotes stem cell recruitment, and improves skin barrier function. According to research published in the Journal of Dermatological Science, the combination creates synergistic effects where BPC-157 and TB-500 enhance tissue repair while GHK-Cu improves tissue quality and appearance. The formulation specifically targets the wound healing cascade at multiple points: inflammation reduction (BPC-157), cellular proliferation (TB-500), and tissue remodeling (GHK-Cu), while also addressing cosmetic concerns through enhanced collagen synthesis and antioxidant protection.

THERAPEUTICAL INDICATIONS

Dragon Pharma Glow 60 mg is indicated for: comprehensive skin rejuvenation and anti-aging treatments, acceleration of musculoskeletal injury recovery (tendonitis, ligament tears, muscle strains), reduction of fine lines, wrinkles, and skin laxity, improvement of skin texture, elasticity, and hydration, enhancement of post-surgical wound healing and scar reduction, treatment of chronic inflammatory conditions (arthritis, bursitis), support of connective tissue health in athletes, management of age-related skin changes and photoaging, improvement of overall tissue quality and resilience, and general regenerative support for active individuals. It's particularly valuable for bodybuilders and athletes seeking both performance recovery and aesthetic improvement, individuals with aging skin concerns, those recovering from surgical procedures, and anyone seeking comprehensive tissue regeneration benefits.

DOSES AND METHOD OF ADMINISTRATION

Reconstitute the 60 mg vial with 1-2 mL of bacteriostatic water to achieve concentrations of 30-60 mg/mL. Standard dosing protocols: For systemic effects: 300-600 mcg (0.3-0.6 mg) administered subcutaneously daily or every other day. For skin rejuvenation: 200-400 mcg daily, with potential for microneedling or localized subcutaneous administration in areas of concern. For injury recovery: 400-600 mcg daily, with consideration for localized injection near injury sites. For anti-aging maintenance: 200-300 mcg every other day. Administration should be subcutaneous for systemic and skin benefits, or intramuscular for deeper tissue targeting. For facial rejuvenation, micro-droplet subcutaneous administration in facial areas may be employed by experienced users. Treatment cycles typically last 8-12 weeks with 4-6 week breaks between cycles. Always begin with lower doses to assess individual tolerance and response.

CYCLE/STACKING

Glow stacks synergistically with various compounds to enhance specific regenerative and aesthetic outcomes. Combine with GHK-Cu 50 mg for amplified collagen synthesis and skin rejuvenation effects. Stack with Epitalon 50 mg for comprehensive anti-aging benefits through telomere support alongside tissue regeneration. For enhanced recovery from intense training, add IGF-1 LR3 to promote muscle repair alongside connective tissue healing. During cutting phases when skin elasticity is challenged, combine with Primobolan 100 to maintain skin quality despite fat loss. For comprehensive cellular health support, include NAD+ to enhance mitochondrial function alongside tissue regeneration from Glow.

POST CYCLE THERAPY

Glow serves as an excellent adjunct during post-cycle therapy by addressing the cumulative tissue stress and potential skin changes that often accompany anabolic cycles. The GHK-Cu component helps maintain skin elasticity and quality during the hormonal fluctuations of PCT, while BPC-157 and TB-500 support recovery of any training-related injuries that may become apparent as water retention subsides. Administer 200-400 mcg daily during PCT to support connective tissue health, improve recovery between workouts, and maintain skin appearance during the transition period. The anti-inflammatory properties are particularly valuable when discontinuing compounds that may have masked joint or connective tissue issues. Continue Glow for 4-6 weeks post-cycle to maximize regenerative benefits during the recovery phase. Unlike hormonal compounds, Glow doesn't interfere with HPTA recovery and may actually support overall tissue health during this sensitive period.

SIDE EFFECTS

Glow is generally well-tolerated with minimal side effects when used at recommended doses. Some users report mild injection site reactions (redness, itching, or discomfort) that typically resolve within 24-48 hours. The GHK-Cu component may cause temporary skin flushing or a mild metallic taste in the mouth, particularly at higher doses. Rare side effects include temporary fatigue, headache, or mild nausea during initial adaptation. Unlike hormonal compounds, Glow doesn't cause androgenic, estrogenic, or progestogenic side effects. There is no risk of hormonal suppression, hair loss, or gynecomastia. Allergic reactions are extremely rare but possible in sensitive individuals. Most side effects are transient and diminish with continued use or dose reduction. The favorable safety profile makes Glow suitable for long-term use with appropriate cycling.

CONTRAINDICATIONS

Contraindications include known hypersensitivity to any component of the formulation (BPC-157, TB-500, GHK-Cu, or copper). Individuals with copper metabolism disorders (Wilson's disease, Menkes disease) should avoid GHK-Cu containing products. Not recommended during pregnancy or lactation due to limited safety data. Use with caution in individuals with active cancer or recent malignancy history, as peptides may theoretically stimulate cell proliferation. Those with bleeding disorders or on anticoagulant therapy should consult a healthcare provider before use due to potential angiogenic effects. Not for use in individuals under 21 years of age. Individuals with autoimmune conditions affecting skin or connective tissues should use under medical supervision. Those with known allergies to copper or copper-containing compounds should avoid use.

OVERDOSE

Acute overdose is unlikely due to the peptide nature of the compounds and their rapid metabolism. Symptoms of excessive dosing may include pronounced injection site reactions, systemic fatigue, headache, gastrointestinal discomfort, or excessive skin flushing from GHK-Cu. In cases of significant overdose, discontinue use and allow peptides to clear from the system (typically 24-48 hours). Supportive care includes hydration and rest. No specific antidotes exist, but symptoms are self-limiting. The wide therapeutic index makes serious overdose complications extremely rare. Copper toxicity from GHK-Cu would require massive overdose far beyond recommended doses and is not a concern with proper use. Always follow recommended dosing guidelines based on individual goals and response.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

Use sterile technique for reconstitution and injection to prevent infection. Rotate injection sites regularly to prevent tissue damage or lipoatrophy. For skin rejuvenation applications, proper injection technique is crucial to avoid uneven results or complications. Monitor for signs of allergic reaction, especially during initial use. Individuals with autoimmune conditions should use with caution and monitor symptoms. Avoid concurrent use with immunosuppressive medications unless under medical supervision. Regular monitoring of liver function and copper levels may be advisable during extended use. Discontinue use 2 weeks before scheduled surgery due to potential effects on wound healing and angiogenesis. Store reconstituted solution refrigerated and use within 7 days. Avoid sun exposure immediately after facial injections to prevent hyperpigmentation.

INTERACTIONS WITH OTHER DRUGS

Potential interactions include: enhanced effects when combined with other healing peptides or growth factors, possible interference with immunosuppressive medications, potential additive effects with anti-inflammatory drugs, and synergistic actions with collagen supplements or skin treatments. GHK-Cu may interact with zinc supplements, potentially altering mineral balance. Copper-containing compounds may affect absorption of certain antibiotics (tetracyclines, quinolones). No significant interactions with most anabolic steroids have been reported, though regenerative peptides may help mitigate some steroid-related connective tissue issues. Always inform healthcare providers of all supplements and medications being used. Those using copper IUDs or other copper-containing medical devices should consult with a healthcare provider before using GHK-Cu containing products.

PRESENTATION, PACKAGING

Dragon Pharma Glow 60 mg is presented in sterile 2 mL glass vials with gray rubber stoppers and gold aluminum seals. Each vial contains 60 mg of lyophilized peptide blend (10 mg BPC-157, 10 mg TB-500, 40 mg GHK-Cu). Product is available in packs of 3, 5, or 10 vials, often with bacteriostatic water included. Each vial is individually labeled with product name, strength, batch number, expiration date, and unique serial number for authenticity verification. Packaging includes tamper-evident features and discreet outer packaging for privacy. Instructions for reconstitution and administration are included, with special guidance for skin rejuvenation applications. The gold packaging distinguishes Glow as a premium regenerative complex within Dragon Pharma's product lineup.

STORAGE

Store unopened vials at 2-8°C (36-46°F) in refrigerator. Do not freeze. Protect from light. After reconstitution, store at 2-8°C (36-46°F) and use within 7 days. Do not use if solution appears cloudy, discolored, or contains particulate matter. Avoid temperature fluctuations. For travel, use insulated containers with cold packs. Long-term storage (over 6 months) should maintain constant refrigeration. Shelf life of unopened vials is 24 months when stored properly. Keep out of reach of children and pets. For skin rejuvenation protocols requiring multiple small doses, consider dividing reconstituted solution into sterile vials to minimize repeated punctures of the primary vial.

DELIVERY TO THE USA

All orders to the United States are shipped discreetly with guaranteed delivery. We utilize multiple shipping carriers with temperature-controlled options available for peptide products. Most orders arrive within 7-10 business days with tracking provided upon shipment. Packaging is plain and unmarked to ensure privacy. We offer reshipment guarantee for orders lost in transit or seized by customs, though seizure rates for research peptides are extremely low. Express shipping options available for urgent needs. All packages require signature confirmation for security. For skin rejuvenation protocols requiring consistent supply, subscription options with regular delivery are available to ensure treatment continuity.

LEGAL STATUS

In the United States, Glow and its component peptides are sold for research purposes only under the provisions of the Dietary Supplement Health and Education Act (DSHEA). They are not FDA-approved for human consumption but are legal to purchase and possess for research. Not for human consumption, diagnosis, or treatment of any disease. Purchasers assume all responsibility for compliance with local laws. In sports competitions, check specific federation rules as some organizations prohibit certain peptides. Always consult with a healthcare professional before beginning any new supplement regimen, particularly for aesthetic or medical applications.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• National Institutes of Health - Peptides in Dermatology and Wound Healing

PROFILE

• Chemical names: BPC-157 (Body Protection Compound), TB-500 (Thymosin Beta-4), GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper Complex)
• Molecular formulas: C62H98N16O22 (BPC-157), C212H350N56O78S (TB-500), C14H24CuN6O4 (GHK-Cu)
• Molecular weights: 1419.55 g/mol (BPC-157), 4963.49 g/mol (TB-500), 419.92 g/mol (GHK-Cu)
• Percentage of anabolic activity: 0% (Not anabolic)
• Percentage of androgenic activity: 0% (Not androgenic)
• Active half life: 4-6 hours (BPC-157), 2-4 hours (TB-500), 2-3 hours (GHK-Cu)
• Recommended dosage: 200-600 mcg daily
• Acne: None reported
• Bloating (water retention): None reported
• HBR (Hepatobiliary-related): No hepatotoxicity
• Hepatic toxicity: None
• Aromatization: Does not aromatize
• Detection time: 24-72 hours
• Anabolic/Androgenic Ratio: N/A
• Ratio composition: 1:1:4 (BPC-157:TB-500:GHK-Cu)
• Primary mechanisms: Angiogenesis, cell migration, collagen synthesis